Targeting aggressive rare biliary malignancies through rigorous peer-reviewed grants

Our scientific advisory board directs capital toward high-impact clinical bottlenecks where focused funding accelerates patient outcomes.

Biomarker discovery & genomic profiling

Targeted trial navigation & cohorts

Biospecimen bank infrastructure

Mapping FGFR, HER2, and MSI-H alterations in gallbladder adenocarcinomas to match patients with precision targeted therapies.

Funding specialized clinical trial coordination to expand patient access to emerging Phase I and Phase II immunotherapy protocols.

Building robust tissue repositories that allow researchers worldwide to study rare biliary tumor microenvironments safely.

Measurable progress in specialized oncology

100%

designated research allocation

8

peer-reviewed publications

3

multicenter consortiums

Review our upcoming grant cycle criteria

We invite academic oncologists, clinical researchers, and institutional partners to examine our funding guidelines and submit LOIs.